eClinical Technology and Industy News

Cannabics Pharmaceuticals to launch Drug Development Programs for Prostate Cancer and Neurodegenerative & Mental Health Diseases

Excerpt from the Press Release:

TEL AVIV, Israel and BETHESDA, Maryland, June 17, 2021 /PRNewswire/ — Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today the expansion of its research program with new drug development projects targeting Prostate Cancer, Neurodegenerative & Mental Health diseases. The announcement of the new research projects follows promising initial preclinical results obtained in the company’s in-house drug discovery facility in Rehovot, Israel. Study results indicate the potential efficacy of a variety of specific analytes for the indications tested. The experiments performed were conducted on cell lines and human biopsies obtained under Helsinki Committee approval. The company plans to continue development of these drug candidates and continue testing with animal models while entering a drug regulatory development route for each indication.

This announcement also comes following the company’s promising animal model study results for company’s proprietary Colorectal Cancer treatment drug candidate RCC-33. The company has also recently announced a decision to enter the Melanoma and Breast Cancer markets with new drug development projects.

Click the button below to read the entire Press Release:

Continue Reading The Press Release

Discover What Sets TrialStat Apart From Ordinary EDC Platforms

Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?